GLP-2: Dual GIP/GLP-1 Receptor Agonist

What is GLP-2?

GLP-2 is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It represents a new class of peptides that simultaneously targets two incretin receptors, offering a unique approach to metabolic research.

Dual Mechanism of Action

Unlike single-receptor agonists such as GLP-1, GLP-2 activates both:

GIP Receptor Activation

• Enhances insulin sensitivity in adipose tissue
• Promotes lipid metabolism and fat oxidation
• Modulates bone metabolism
• Contributes to energy expenditure regulation

GLP-1 Receptor Activation

• Reduces appetite through hypothalamic signaling
• Slows gastric emptying
• Stimulates glucose-dependent insulin secretion
• Suppresses glucagon release

Clinical Evidence

SURMOUNT Trials

• SURMOUNT-1: Demonstrated up to 22.5% body weight reduction at the highest dose over 72 weeks — the largest weight reduction ever seen with a non-surgical intervention.
• SURMOUNT-2: In type 2 diabetes participants, showed 14.7% weight reduction with improved glycemic control.
• SURMOUNT-3: Combined with lifestyle intervention, achieved up to 26.6% total weight loss.

Comparison with GLP-1

Research Applications

• Advanced metabolic syndrome models
• Comparative incretin receptor studies
• Cardiovascular risk reduction research
• NAFLD/NASH investigation
• Combination therapy research with other peptides

Available Research Formats

• Lyophilized vials: Standard format for subcutaneous research
• Nasal spray: Emerging delivery method under investigation

Conclusion

GLP-2's dual-receptor mechanism represents a paradigm shift in metabolic peptide research. Its superior efficacy in clinical trials has made it one of the most sought-after research peptides for metabolic studies.